Journal of substance use and addiction treatment最新文献

{"title":"“Now that I'm here, I actually have the stability and the time to really think about stuff like that”: Perspectives on medications for opioid use disorder in low-threshold harm reduction housing","authors":"Avik Chatterjee ,&nbsp;Sabrina S. Rapisarda ,&nbsp;Joseph Silcox ,&nbsp;Sofia Zaragoza ,&nbsp;Charlie Summers ,&nbsp;Andrew Rolles ,&nbsp;Sarah Kosakowski ,&nbsp;Traci C. Green","doi":"10.1016/j.josat.2025.209810","DOIUrl":"10.1016/j.josat.2025.209810","url":null,"abstract":"<div><div>Sweeping of encampments is one policy approach to the growing visibility of homelessness and substance use in U.S. cities but is associated with increased overdose deaths. In 2022, to mitigate the impacts of a sweep, the City of Boston created seven harm reduction housing (HRH) sites to accommodate displaced individuals. HRH sites offered on-site or off-site medications for opioid use disorder (MOUD). As part of a broader parent study, we recruited 28 residents from HRH sites previously enrolled in a survey for semi-structured interviews, exploring their experiences with housing, the current HRH site, substance use, service access, overdose, MOUD, and more. We engaged in an inductive thematic analysis of the MOUD interview data. Four themes emerged from thematic analysis: (1) HRH sites afforded participants on-site access and linkages that facilitated MOUD initiation and retention; (2) when off-site, location, transportation and accessibility issues limited MOUD access; (3) MOUD prescribing policies at HRH sites were uniquely low-threshold; and (4) HRH-related MOUD engagement shaped health-related outcomes. Participants reported that HRH facilitated ease of access and delivery of MOUD both on and off site, raised considerations about how MOUD is accessed through HRH, and described how MOUD through HRH changed their substance use behaviors, health, and quality of life. Government entities that opt to clear encampments as a policy approach to address homelessness and substance use should also implement HRH interventions that facilitate MOUD access in conjunction. Such an approach would mitigate known harms associated with sweeps.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"179 ","pages":"Article 209810"},"PeriodicalIF":1.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145159074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overdose risk profiles in pregnancy: Latent class analysis of pregnant individuals with opioid use disorder.","authors":"Elysha Cash, Gerald Cochran, Marcela C Smid, Jasmin E Charles, Grace Humiston, Yingjia Wei, Nicole Mauerman, Kristi Carlston, Grace Broussard, Britnee Sengpraseut, Peter R Martin, T John Winhusen","doi":"10.1016/j.josat.2025.209809","DOIUrl":"10.1016/j.josat.2025.209809","url":null,"abstract":"<p><strong>Introduction: </strong>Given the continued rise in opioid exposed pregnancies and overdose during the postnatal period, it is critical to identify risk characteristics among this population to enable clinicians to better tailor interventions. This exploratory study sought to develop a deeper understanding of overdose risk characteristics among pregnant people with opioid use disorder and which characteristics may contribute to differing risk profiles.</p><p><strong>Methods: </strong>Design and participants. This exploratory secondary analysis utilized baseline data from a large-scale national multi-site randomized controlled trial that compared two buprenorphine formulations among treatment seeking pregnant individuals with opioid use disorder.</p><p><strong>Assessments: </strong>For risk group identification, the Personal Opioid-Overdose Risk Survey was used. Trauma history experience was assessed using the Trauma History Screen and substance use history was captured using the DSM-5 Checklist and Treatment Services Review V6.</p><p><strong>Analyses: </strong>Latent class analysis identified unique subgroups of participants based on overdose risk factors. Latent class group membership was associated with trauma history and substance use characteristics using logistic and stepwise logistic regression.</p><p><strong>Results: </strong>Three distinct classes of overdose risk emerged: the tolerance and polysubstance/alcohol use (HIGH-ALC) class (n = 14, 10 %), synthetic opioid and polysubstance use (LOW-ALC/FENT) class (n = 65, 46.4 %), and the low risk (LOW-RISK) class (n = 61, 43.6 %). The HIGH-ALC class reported the most (non-opioid) substance use in the last 12 months with 6 times higher odds of marijuana use (95 % CI, 1.01-35.67) and 17.48 times higher odds of cocaine use (95 % CI, 3.45-88.48) compared to the LOW-RISK class. The LOW-ALC/FENT class (n = 65, 46.4 %) had the highest reports of childhood physical abuse, greater odds of experiencing intimate partner violence regarding recovery (OR = 4.82, 95 % CI = 1.90-12.26), and greater odds of a threat to safe living (OR = 3.35, 95 % CI = 0.72-15.66). The LOW-RISK class (n = 61, 43.6 %) had the lowest reports of polysubstance use in the last 12 months and the least reports of both childhood sexual trauma and adulthood sexual trauma.</p><p><strong>Conclusions: </strong>Through better understanding distinct patient overdose risk profiles, healthcare providers can deliver more targeted prevention interventions to address individual needs and improve maternal outcomes.</p><p><strong>Trial registration: </strong>NCT03918850.</p>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":" ","pages":"209809"},"PeriodicalIF":1.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12742178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TOC (update)","authors":"","doi":"10.1016/S2949-8759(25)00183-3","DOIUrl":"10.1016/S2949-8759(25)00183-3","url":null,"abstract":"","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"178 ","pages":"Article 209804"},"PeriodicalIF":1.9,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145094797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of direct induction onto long-acting injectable buprenorphine","authors":"Thileepan Naren ,&nbsp;Dean Membrey ,&nbsp;Paul MacCartney ,&nbsp;Ryan D'Cunha ,&nbsp;Suzanne Nielsen ,&nbsp;Sarah Garry","doi":"10.1016/j.josat.2025.209808","DOIUrl":"10.1016/j.josat.2025.209808","url":null,"abstract":"<div><h3>Introduction</h3><div>When first introduced, induction onto long-acting injectable buprenorphine (LAIB) required a period of stabilization on sublingual buprenorphine, presenting a key treatment barrier for some patients. Recent regulatory changes allow for direct induction on a low-dose weekly LAIB preparation, yet few studies have examined direct induction onto higher dose weekly and monthly LAIB formulations. To address this gap, this case series reports on 129 patients who were commenced directly onto any LAIB preparation.</div></div><div><h3>Methods</h3><div>A retrospective audit and analysis of the electronic medical record at an urban low-threshold primary healthcare service providing care to a marginalized population of people who inject drugs in Melbourne, Victoria. The study extracted data for all patients who were commenced directly onto LAIB between 1st January 2024 to 31st December 2024.</div></div><div><h3>Results</h3><div>The study identified patients (<em>n</em> = 129) commenced directly onto any formulation of LAIB. Four patients (3 %) experienced precipitated withdrawal post direct induction onto LAIB, requiring unplanned medical review and symptomatic management but not hospitalization. No other adverse reactions were identified. Most (<em>n</em> = 85, 65.9 %) returned for their next LAIB dose with 57.4 % (<em>n</em> = 74) retained in LAIB treatment at three months.</div></div><div><h3>Conclusion</h3><div>This case series provides evidence that direct induction onto LAIB is feasible with rates of precipitated withdrawal similar to those previously reported for sublingual buprenorphine induction. Given the benefits of direct induction, in suitably screened patients this could be considered to be a preferred method of LAIB induction.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"179 ","pages":"Article 209808"},"PeriodicalIF":1.9,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"C2: editorial board","authors":"","doi":"10.1016/S2949-8759(25)00182-1","DOIUrl":"10.1016/S2949-8759(25)00182-1","url":null,"abstract":"","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"178 ","pages":"Article 209803"},"PeriodicalIF":1.9,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145094798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring social connections and mental well-being among members of a sober active community: A social network analysis","authors":"Megan S. Patterson ,&nbsp;Yunlin Zhou ,&nbsp;Anjorin E. Adeyemi ,&nbsp;Shuai Ma ,&nbsp;Linlin Luo ,&nbsp;Allison N. Francis ,&nbsp;Zhenning Kang ,&nbsp;Katie M. Heinrich ,&nbsp;Tyler Prochnow","doi":"10.1016/j.josat.2025.209801","DOIUrl":"10.1016/j.josat.2025.209801","url":null,"abstract":"<div><h3>Introduction</h3><div>Addiction is a complex and pervasive condition which affects physical, social, and mental health. Research consistently shows that social support and social networks are key to the addiction recovery process (defined as a process of change through which individuals improve their health and wellness, live a self-directed life, and strive to reach their full potential) and recovery communities available outside of or in conjunction to formal treatment are effective in providing such support. This study investigated social networks and psychological distress among members of <em>The Phoenix</em>, a sober active community that incorporates group-based exercise (e.g., CrossFit) into the recovery process.</div></div><div><h3>Methods</h3><div>Using Social Network Analysis (SNA), we analyzed relationships within <em>The Phoenix</em> CrossFit programs in Denver, Colorado (N = 35) and Wichita, Kansas (N = 42). Linear Network Autocorrelation Models (LNAMs) assessed whether social network positions and connections related to psychological distress among members, and Exponential Random Graph Models (ERGMs) explored factors that explained the presence of supportive relationships between <em>Phoenix</em> members.</div></div><div><h3>Results</h3><div>Network centrality, such as being identified as a source of support (i.e., in-degree), was associated with lower psychological distress, while peripheral positions correlated with higher psychological distress in both networks. Additionally, individuals experiencing higher psychological distress tended to seek more supportive connections, whereas those with lower distress were more frequently nominated as supportive figures.</div></div><div><h3>Conclusions</h3><div>These results highlight the potential of community-based recovery resources like <em>The Phoenix</em> to foster social networks that promote mental well-being.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"179 ","pages":"Article 209801"},"PeriodicalIF":1.9,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145066599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decisional needs of intensive care unit survivors with alcohol use disorder considering alcohol treatment: A qualitative study","authors":"Kelsey Hills-Dunlap ,&nbsp;Christopher E. Knoepke ,&nbsp;Daniel D. Matlock ,&nbsp;Ellen L. Burnham ,&nbsp;Marc Moss ,&nbsp;Sarah E. Jolley ,&nbsp;Caroline K. Tietbohl","doi":"10.1016/j.josat.2025.209798","DOIUrl":"10.1016/j.josat.2025.209798","url":null,"abstract":"<div><h3>Introduction</h3><div>Alcohol use disorder (AUD) is a common and serious medical condition with substantial global public health impact, and it is prevalent among patients admitted to intensive care units (ICUs) in the United States. Many ICU survivors with AUD report motivation to change their drinking, however, few receive alcohol treatment. We sought to understand the decision support needs of ICU survivors with AUD when faced with choices about alcohol treatment options.</div></div><div><h3>Methods</h3><div>In this qualitative study, we completed 17 semi-structured interviews with hospitalized patients with AUD recruited from two urban hospitals in the United States after an alcohol-related ICU admission. We used a reflexive thematic analysis and a deductive and inductive coding approach, with a-priori codes developed from the Ottawa Decision Support Framework.</div></div><div><h3>Results</h3><div>Participants described any prior experience with alcohol treatment decisions and their current decision-making process regarding engagement with alcohol treatment after ICU admission. In our analysis, we developed four themes and associated subthemes: (1) Decisional needs included knowledge of alcohol's impact on health issues, awareness of treatment options, and trust in the recovery process; (2) Priorities regarding treatment options centered on cost, lifestyle integration, and personal experiences with addiction among treatment program staff; (3) Values regarding the decision making process included a sense of autonomy, relatedness to information providers, and productive involvement of social supports; (4) Decision aids should incorporate video formats to deliver transparent information regarding alcohol treatment options.</div></div><div><h3>Conclusions</h3><div>Decisional needs of ICU survivors with AUD who are considering alcohol treatment reflect the importance of patient-centered information and consideration of patient preferences and values in alcohol treatment decisions. These findings will inform the development of an alcohol treatment decision aid to address these decisional needs and facilitate engagement with alcohol treatment for ICU survivors with AUD.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"179 ","pages":"Article 209798"},"PeriodicalIF":1.9,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145066658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-overdose outreach programs in Massachusetts before and after the onset of the COVID-19 pandemic","authors":"Alexander Y. Walley ,&nbsp;Jiayi Wang ,&nbsp;C. To ,&nbsp;MaryKate Duska ,&nbsp;Stephen Murray ,&nbsp;Moriah Wiggins ,&nbsp;Andrew Rolles ,&nbsp;Shapei Yan ,&nbsp;Sarah Kosakowski ,&nbsp;Sarah M. Bagley ,&nbsp;Ziming Xuan ,&nbsp;Justeen Hyde ,&nbsp;Scott W. Formica","doi":"10.1016/j.josat.2025.209799","DOIUrl":"10.1016/j.josat.2025.209799","url":null,"abstract":"<div><h3>Purpose</h3><div>To describe the characteristics of Massachusetts post-overdose outreach programs before and after the onset of the COVID-19 pandemic and identify program adaptations and practices.</div></div><div><h3>Methods</h3><div>We surveyed Massachusetts post-overdose programs about programming onset, funding, outreach encounters, naloxone distribution, medication for opioid use disorder (MOUD) referrals, and program practices before and after the onset of the COVID-19 pandemic. We calculated frequencies and summary statistics for program characteristics and practices. We compared programs that started before and after the onset of the COVID-19 pandemic using Pearson Chi-squared and Fisher's Exact tests.</div></div><div><h3>Results</h3><div>As of July 2022, we identified 256 programs active in 242 (69 %) of Massachusetts' 351 municipalities. Before March 2020, 160 “pre-pandemic onset” programs were active. After March 2020, 96 “post-pandemic onset” programs started. In 2022, most were grant funded (89 % (227/256)). Initial survivor contact was attempted via phone (79 % (201/256)) and text (47 % (120/256)), most commonly by a recovery coach (77 % (196/256)). Most programs offered fentanyl test strips and naloxone. Some programs, more commonly pre-pandemic onset, offered safer smoking and injecting supplies. Among the 160 pre-pandemic onset programs, new practices included recommending virtual spotting (44 % (70/160)), facilitating MOUD telemedicine (24 % (39/160)), outreach for people using cocaine and methamphetamine (42 % (67/160)), and referring to race and ethnicity congruent services (31 % (50/160)).</div></div><div><h3>Conclusion</h3><div>Massachusetts post-overdose outreach programs expanded following the COVID-19 pandemic onset. Services and innovations included resources to reduce harms from the unregulated drug supply (e.g., fentanyl test strips) and more inclusive outreach (e.g., include people using stimulants and race and ethnicity congruent services).</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"179 ","pages":"Article 209799"},"PeriodicalIF":1.9,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145056394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"U.S. states opting out of expanded methadone take-home policies and associated mortality","authors":"Victor Roy ,&nbsp;Michele J. Buonora ,&nbsp;Cristina Murray-Krezan ,&nbsp;Anthony Fabio ,&nbsp;Paul J. Joudrey","doi":"10.1016/j.josat.2025.209800","DOIUrl":"10.1016/j.josat.2025.209800","url":null,"abstract":"<div><h3>Background</h3><div>Historically, federal regulations limited take-home methadone doses largely due to concerns about methadone-related overdose. In response to the COVID-19 pandemic, an emergency federal policy in March 2020 permitted states to expand take-home methadone doses. Our objective was to utilize state-level variation in take-home expansion to compare changes in methadone related overdose death rates among states that opted into and then out of expanded take-home dosing with states that opted into and continued the policy.</div></div><div><h3>Methods</h3><div>We used an extended two-way fixed effects difference-in-differences (DID) approach. The intervention group included states that initially opted into and then out of expanded take-home dosing, while the comparison group included states that opted into and continued the policy. Our primary outcome was the average treatment effect on the treated states (ATET) using quarterly rate of methadone-related overdose deaths per 100,000 persons from April 2020 to December 2022. Data sources included a state policy review, CDC WONDER, and U.S. Census Bureau.</div></div><div><h3>Results</h3><div>The intervention group included three states that opted out of expanded take-home dosing, while the comparison group comprised 16 states maintaining the policy. We found no significant association between opting out of expanded take-home dosing and methadone-related overdose death rates [ATET = 0.02, 95 % CI = (−0.03, 0.47), <em>p</em> = 0.47]. Adjustments for non-methadone-related overdose variables yielded similar results.</div></div><div><h3>Conclusion</h3><div>States who continued expanded take-home methadone dosing did not subsequently experience a detectable increase in methadone-related overdose deaths relative to states that opted out of the policy. This evidence suggests that policies expanding methadone take-homes are safe at a population level, which can inform deliberations within states that currently maintain strict restrictions.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"179 ","pages":"Article 209800"},"PeriodicalIF":1.9,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145024860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of psychostimulant prescription on opioid use disorder among people with co-occurring ADHD","authors":"Mohammad Yaseliani ,&nbsp;Youngsuhk Jo ,&nbsp;Lake Lindo ,&nbsp;Jabed Al Faysal ,&nbsp;Md Mahmudul Hasan","doi":"10.1016/j.josat.2025.209794","DOIUrl":"10.1016/j.josat.2025.209794","url":null,"abstract":"<div><h3>Importance</h3><div>Attention-deficit/hyperactivity disorder (ADHD) is a condition often comorbid with substance use disorders. With the increase in opioid and stimulant overdoses, there remains concern regarding the appropriateness of psychostimulants for patients on maintenance therapy for opioid use disorder (OUD) with co-occurring ADHD.</div></div><div><h3>Objectives</h3><div>To assess the impact of psychostimulant use on outcomes of OUD maintenance therapy with buprenorphine based on rates of (1) treatment discontinuation and (2) opioid-related hospitalization.</div></div><div><h3>Design, setting, and participants</h3><div>This present investigation used a retrospective cohort study design consisting of a secondary analysis of data collected from IBM MarketScan Commercial claims from 2011 to 2021. Individuals were aged 12 to 64 with concurrent ADHD and OUD diagnosis receiving buprenorphine treatment.</div></div><div><h3>Exposures</h3><div>Presence of psychostimulant prescriptions.</div></div><div><h3>Main outcomes and measures</h3><div>Primary outcomes were buprenorphine discontinuation and opioid-related hospitalization.</div></div><div><h3>Results</h3><div>Study sample included 10,712 individuals with comorbid ADHD and OUD (mean age of 31.7 years, SD 10.9) who initiated buprenorphine maintenance therapy. 5190 individuals received psychostimulant prescriptions while 5522 individuals did not. Individuals who received psychostimulants demonstrated lower odds of buprenorphine discontinuation (OR = 0.669, 95 % CI = 0.610, 0.734) and hospitalization (OR = 0.493, 95 % CI = 0.418, 0.581). A one-unit increase in the psychostimulant fill count (IRR = 0.580, 95 % CI = 0.493, 0.683) was associated with a lower incidence rate of hospitalization.</div></div><div><h3>Conclusions</h3><div>In patients with a dual diagnosis of ADHD and OUD on buprenorphine therapy, treatment of ADHD with prescription psychostimulants is associated with improved adherence to buprenorphine and lower odds of opioid-related hospitalization.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"179 ","pages":"Article 209794"},"PeriodicalIF":1.9,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}